Taiwan Food & Drug Administration approves Moderna’s COVID-19 mRNA vaccine targeting SARS-COV-2 variant JN.1

CAMBRIDGE, MA / ACCESSWIRE / September 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Taiwan Food & Drug Administration (FDA) has approved an updated formulation of its COVID-19 mRNA vaccine Spikevax. The vaccine targets the SARS-CoV-2 variant JN.1. and is intended for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older.

In April 2024The World Health Organization (WHO) Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) has issued guidelines recommending the use of a monovalent JN.1 line for the antigen composition of the COVID-19 vaccine.